MAPT and Alzheimer disease: Hence, these findings extend the previous literature on CSF AD biomarker changes in OSA patients and add evidence that p-tau protein alteration may reflect the presence of synaptic damage, neurodegeneration, and neuronal dysfunction, and the modification of brain glucose uptake documented by 18F-FDG PET as a result [67].